Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

Biol Blood Marrow Transplant. 2012 Apr;18(4):652-4. doi: 10.1016/j.bbmt.2011.12.587. Epub 2012 Jan 9.

Authors

Giovanni Caocci, Adriana Vacca, Antonio Ledda, Francesca Murgia, Eugenia Piras, Marianna Greco, Marcella Arras, Sandra Atzeni, Roberto Littera, Giorgio La Nasa

PMID: 22240733
DOI: 10.1016/j.bbmt.2011.12.587

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Combined Modality Therapy
Dasatinib
Disease-Free Survival
Female
Follow-Up Studies
Fusion Proteins, bcr-abl / antagonists & inhibitors
Hematopoietic Stem Cell Transplantation*
Humans
Male
Middle Aged
Philadelphia Chromosome*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / administration & dosage
Pyrimidines / therapeutic use*
Remission Induction
Secondary Prevention
Thiazoles / administration & dosage
Thiazoles / therapeutic use*
Transplantation Conditioning*
Transplantation, Autologous
Transplantation, Homologous

Substances

Protein Kinase Inhibitors
Pyrimidines
Thiazoles
Fusion Proteins, bcr-abl
Dasatinib